A Novel Aliphatic 18F-Labeled Probe for PET Imaging of Melanoma

Radiofluorinated benzamide and nicotinamide analogues are promising molecular probes for the positron. emission tomography (PET) imaging of melanoma. Compounds containing aromatic (benzene or pyridine) and N,N-,diethylethylenediamine groups, have been successfully used for :development of :Melanin targeted PET and single photon emission. computed tomography (SPECT) imaging agents for melanoma. The objective of this study was to determine the feasibility of using aliphatic Compounds as a molecular platform for the development of a new generation of PET probes for Melanoma detection. An aliphatic,N,N-diethylethylenediamine precursor was directly coupled to a radiofluorination synthon, p-nitrophenyl 2-F-18-fluoropropionate (F-18-NFP), to produce the probe N-(2-(diethylamino)ethyl)-2-F-18-fluoropropanamide (F-18-FPDA). The melanoma-targeting ability of F-18-FPDA was further evaluated both in vitro and in vivo through cell uptake assays, biodistribution studies, and small animal PET imaging in C57BL/6 mice bearing B16F10 murine melanoma tumors. Beginning with the precursor F-18-NFP, the total preparation time for F-18-FPDA, including the final high-performance liquid chromatography purification step, was approximately 30 min, with a decay corrected radiochemical yield of 79.8%. The melanin targeting specificity of F-18-FPDA was demonstrated by significantly different Uptake rates in tyrosine treated and untreated B16F10 cells in vitro. The tumor uptake of F-18-FPDA in vivo reached 2.65 +/- 0.48 %ID/g. at 2 h postinjection (p.i.) in pigment-eniiched B16F10 xenografts, whereas the tumor uptake of F-18-FPDA was close to the background levels, with rates of only 037 +/- 0.07:%ID/g at 2.h p.i. in the nonpigmented U87MG tumor mouse model. Furthermore, small animal PET imaging studies revealed that F-18-FPDA specifically targeted the melanotic B16F10 tumor, yielding a tumor-to-muscle:ratio of approximately 4:1 at 1 h.p.i and. 7:1.at 2 h p.i. In summary, we report the development of a novel F-18 labeled aliphatic compound for melanoma imaging that can be easily synthesized in high yields using the radiosynthon F-18-NFP the PET probe F-18-FPDA exhibits high B16F10 tumor targeting efficacy and favorable in vivo pharmacokinetics. Our study demonstrates that aliphatic compounds can be used as a new generation molecular platform for the development of novel melanoma targeting agents. Further evaluation and optimization Of F-18-FPDA for melanin targeted molecular imaging are therefore warranted.